Vylaris Tablets

Vylaris Tablets 85477-0912-30

Dietary Supplemement

Dispensed by Prescription^†

Vylaris capsules are an orally administered prescription vitamin formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and for patients with occasional constipation to restore and maintain regularity.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.

Vylaris is manufactured in accordance with Current Good Manufacturing Practice for foods, using ingredients that have been approved by the U.S. Food and Drug Administration (FDA) as food additives or are “Generally Recognized as Safe” (GRAS) for their intended use.

Take two tablets once or twice daily with 8-12 oz of water or as directed by a healthcare practitioner.   

CONTRAINDICATIONS
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Vylaris is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS
Tell your doctor if you have kidney problems or thyroid disease. Do not use this product if you have abdominal pain, diarrhea, or loose stools. Rectal bleeding and/or failure to have a bowel movement after the use of a laxative formula may be an indication of a more serious condition. Should this occur, or if you have a known medical condition and are taking this medication, consult your healthcare provider about the risks and benefits prior to taking this or any dietary supplement.

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact Oncora Pharma, LLC, at 1-844-551-9911.

KEEP OUT OF REACH OF CHILDREN

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.]

Vylaris, Metabolic Support

Dietary Supplement

Vegan tablets are light brown and have an oval shape

Bottles contain 30 Tablets 85477-912-30

Manufactured in USA for:
Oncora Pharma, LLC

Dallas TX 75228

Rev. 05/2026

*Oncora Pharma does not represent these product codes to be National Drug Codes (NDC). Product codes are formatted according to standard industry practice, to meet the formatting requirement by pedigree reporting and supply-chain control including pharmacies.

Dispensed by Prescription^† All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision.

This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels increased risk associated with masking of B12 deficiency (pernicious anemia) requires administration under the care of a licensed medical practitioner (61 FR 8760).1-3 The most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription (Rx). This is not an Orange Book product. This product may be administered only under a physician’s supervision and all prescriptions using this product shall be pursuant to state statutes as applicable. The ingredients, indication or claims of this product are not to be construed to be drug claims.

1. Federal Register Notice of August 2, 1973 (38 FR 20750)
2. Federal Register Notice of October 17, 1980 (45 FR 69043, 69044)
3. Federal Register Notice of March 5, 1996 (61 FR 8760)